Company intelligence / Profile preview

Biocodex

Ownership: Private
Development stage: Commercial

Overview

Biocodex markets the world’s leading probiotic yeast drug Saccharomyces boulardii CNCM I‑745®, with extensive clinical validation for gastrointestinal health. Its orphan drug Diacomit® (stiripentol) is approved internationally for Dravet syndrome. The company continues to invest in R&D across microbiota care, women’s health, and rare diseases. Early-stage research suggests potential new uses of Diacomit® in oncology settings[8][6][10].

Therapeutic areas: GastroenterologyOncologyNeurologyWomen's Health
Modalities: Probiotics (notably Saccharomyces boulardii CNCM I-745®)Small molecules (e.g., stiripentol/Diacomit®)
Industry: Biotech

Drug pipeline

7 assets

stiripentol

Approved

6 more assets in the full pipeline.

Request access →

Partnerships

Kinnov Therapeutics

Beyond the preview

Go deeper on Biocodex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biocodex.

Explore the full profile